News

Demand for medications needed for patients who were intubated or put on a ventilator led to some shortages. The CARES Act has some provisions that may help deal with long-standing causes of the drug shortages that plague U.S. healthcare.

Early studies from China suggested that CT scans of the lungs could be used to diagnose the disease. But as PCR tests became available, radiology groups said CT scans should be used more sparingly and in confirmed cases.

A new handbook for facility managers and building owners offers in-depth guidance for how to ensure HVAC systems are properly maintained and upgraded to minimize virus spread.

These are the top 3 drugs recently approved — or soon to be approved by FDA — to watch in 2020.

A new report from the U.C. Berkeley Labor Center and Working Partnerships USA released today shows how technology is likely to impact job quality in healthcare and suggests that technological adoption may accelerate as a result of the COVID-19 pandemic.

Investigational treatment will target marginal zone lymphoma (MZL) and follicular lymphoma (FL).

During the American Society of Clinical Oncology 2020 Annual Meeting, Flatiron Health, Foundation Medicine, and Genentech presented plans for the Prospective Clinico-Genomic study (PCG), a low-interventional pilot that will use a technology-enabled prospective data collection platform to simplify data collection for patients with lung cancer being treated through clinical trials. The idea is collect blood samples using Foundation Medicine’s liquid biopsy assay and analyze the results through Flatiron’s platform, to see if genomic changes can be detected over the course of cancer treatment. Bobby Green, MD, chief medical officer for Flatiron Health, spoke with Managed Healthcare Executive®.

The two PCSK9 inhibitors have fallen far short of expectations. Inclisiran, which works by RNA inference, only needs to be injected twice a year. 

Pharmacy benefit managers are taking steps to be more responsible for the total cost of care and to become more transparent, while adding technology tools to support patients, payers and physicians in a post-COVID-19 world.

The "conservative estimate" assumes that disruption of services ends in six months.

As the pandemic enters its fourth month in the U.S., the Center for Medicare and Medicaid Innovation (the Innovation Center) has announced several changes that, on the whole, increase flexibility for program participants.

Early detection of low blood oxygen levels may detect ‘silent hypoxia’ seen in some patients with COVID-19. But the American Lung Association advises against buying a pulse oximeter unnecessarily.

Payers have used accumulators and maximizers to counteract drug coupons.

Will produce recommendations for policymakers on crucial issues for future of remote care services.

Some hospitals were overwhelmed. But for many providers, COVID-19 has meant the absence of patients - and major drops in revenue. And now there is a possible economic downturn. COVID-19 has hit American healthcare and hit it hard.   

John S. Linehan of Epstein Becker & Green provides an in-depth analysis of drug coupons, coupon accumulators and maximizers and the federal government's halting efforts to regulate them.

John Kalamaras, business intelligence analytics manager of DataGen, chats with Managed Healthcare Executive's Briana Contreras, about the Centers for Medicare and Medicaid Services, or CMS’, recent announcement of the changes they’ve made for participants in their value-based programs, specifically those in bundled-care programs like BPCI Advanced, whose episodes were affected by COVID-19.

A safe, effective vaccine by December 2020 or January 2021?

Cases of the most common type of liver cancer are expected to be increasingly associated with nonalcoholic steatohepatitits (NASH).

The Institute for Clinical and Economic Review appears to be an important source of information for managed care executives making decisions about treatment and cost.

The agency revoked its emergency use authorization (EUA) for the drug, while warning about a dangerous interaction with remdesivir.

Health and healthcare inequities are the most likely explanation for the disproportionate effect.

Understandably, there is a lot of nervousness around how COVID-19 is going to affect the healthcare industry-both in the near-term as well as the distant future. As the organizations that will have to take on a majority of the financial and operational burden of the COVID pandemic, providers will be hit the hardest in the short-term. As a result, a majority of relief, both at federal and local levels, can be expected to be centered around rescuing providers post-COVID.

The unique formulation is a dispersible tablet for children.

How will they match up against ezeimbe, Repatha and Praluent?